Related Experiment Video
Updated: Feb 23, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
Kristopher R Bosse1, Pichai Raman2, Zhongyu Zhu3
1Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target safety and efficacy. Here, we show that GPC2 is a strong candidate immunotherapeutic target in this childhood cancer. We demonstrate high GPC2 expression in neuroblastoma due to MYCN transcriptional activation and/or somatic gain of the GPC2 locus. We confirm GPC2 to be highly expressed on most neuroblastomas, but not detectable at appreciable levels in normal childhood tissues. In addition, we demonstrate that GPC2 is required for neuroblastoma proliferation. Finally, we develop a GPC2-directed antibody-drug conjugate that is potently cytotoxic to GPC2-expressing neuroblastoma cells. Collectively, these findings validate GPC2 as a non-mutated neuroblastoma oncoprotein and candidate immunotherapeutic target.
Insights
Researchers identified Glypican-2 (GPC2) as a promising target for neuroblastoma immunotherapy. GPC2 is highly expressed in neuroblastoma but not in healthy tissues, making it a safe and effective target for new cancer treatments.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Neuroblastoma is a common childhood cancer with limited treatment options.
- Identifying safe and effective immunotherapeutic targets is crucial for improving patient outcomes.
Purpose of the Study:
- To discover novel cell-surface molecules in neuroblastoma for immunotherapeutic targeting.
- To validate Glypican-2 (GPC2) as a potential therapeutic target in neuroblastoma.
Main Methods:
- RNA-sequencing to identify differentially expressed cell-surface molecules.
- Analysis of GPC2 expression in neuroblastoma cell lines and patient tissues.
- Functional studies to assess GPC2's role in neuroblastoma proliferation.
- Development of a GPC2-directed antibody-drug conjugate.
Main Results:
- GPC2 is highly expressed in neuroblastoma, driven by MYCN activation or gene locus gain.
- GPC2 expression is specific to neuroblastoma, with minimal presence in normal childhood tissues.
- GPC2 is essential for neuroblastoma cell proliferation.
- A GPC2-targeted antibody-drug conjugate demonstrated potent cytotoxicity against neuroblastoma cells.
Conclusions:
- GPC2 is a validated neuroblastoma oncoprotein and a promising immunotherapeutic target.
- GPC2 represents a safe and effective target for novel neuroblastoma treatments.
- Targeting GPC2 holds potential for improving outcomes in pediatric neuroblastoma.
